Jonathan M. Kurie

2.4k total citations
18 papers, 907 citations indexed

About

Jonathan M. Kurie is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jonathan M. Kurie has authored 18 papers receiving a total of 907 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 7 papers in Molecular Biology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jonathan M. Kurie's work include Cancer-related Molecular Pathways (4 papers), Cancer-related molecular mechanisms research (3 papers) and Lung Cancer Treatments and Mutations (3 papers). Jonathan M. Kurie is often cited by papers focused on Cancer-related Molecular Pathways (4 papers), Cancer-related molecular mechanisms research (3 papers) and Lung Cancer Treatments and Mutations (3 papers). Jonathan M. Kurie collaborates with scholars based in United States, China and South Korea. Jonathan M. Kurie's co-authors include Don L. Gibbons, Lauren A. Byers, Chad J. Creighton, Waun Ki Hong, Yanan Yang, Ho‐Young Lee, Bingrong Liu, Sandra Wiehle, Kyung‐Hee Chun and Pinchas Cohen and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and Biochemical Journal.

In The Last Decade

Jonathan M. Kurie

18 papers receiving 897 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jonathan M. Kurie United States	13	533	344	302	204	84	18	907
Carmela De Marco Italy	20	691 1.3×	336 1.0×	242 0.8×	195 1.0×	58 0.7×	34	1000
Sylvie Shen Australia	14	447 0.8×	202 0.6×	177 0.6×	171 0.8×	59 0.7×	26	840
Qi-Shan Dai China	21	770 1.4×	289 0.8×	426 1.4×	291 1.4×	41 0.5×	39	1.2k
Libin Sun China	17	444 0.8×	165 0.5×	334 1.1×	285 1.4×	65 0.8×	45	847
Medha S. Darshan United States	8	277 0.5×	145 0.4×	241 0.8×	292 1.4×	73 0.9×	13	731
Morag Seywright United Kingdom	17	481 0.9×	322 0.9×	242 0.8×	311 1.5×	28 0.3×	40	948
Zhimin Liu China	15	357 0.7×	241 0.7×	213 0.7×	68 0.3×	163 1.9×	32	741
William Dahut United States	11	464 0.9×	323 0.9×	190 0.6×	287 1.4×	20 0.2×	19	887
Zhenqing Ye United States	12	455 0.9×	227 0.7×	257 0.9×	247 1.2×	30 0.4×	18	861

Countries citing papers authored by Jonathan M. Kurie

Since Specialization

Citations

This map shows the geographic impact of Jonathan M. Kurie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan M. Kurie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan M. Kurie more than expected).

Fields of papers citing papers by Jonathan M. Kurie

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonathan M. Kurie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan M. Kurie. The network helps show where Jonathan M. Kurie may publish in the future.

Co-authorship network of co-authors of Jonathan M. Kurie

This figure shows the co-authorship network connecting the top 25 collaborators of Jonathan M. Kurie. A scholar is included among the top collaborators of Jonathan M. Kurie based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jonathan M. Kurie. Jonathan M. Kurie is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Kawakami, Masanori, Lisa Maria Mustachio, Yulong Chen, et al.. (2020). A Novel CDK2/9 Inhibitor CYC065 Causes Anaphase Catastrophe and Represses Proliferation, Tumorigenesis, and Metastasis in Aneuploid Cancers. Molecular Cancer Therapeutics. 20(3). 477–489. 13 indexed citations

Lin, Steven H., Lin Xiao, Daniel L. Clay, et al.. (2018). OA01.06 DETERRED: Phase II Trial Combining Atezolizumab Concurrently with Chemoradiation Therapy in Locally Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 13(10). S320–S321. 20 indexed citations

Chen, Limo, Xiaohui Yi, Sangeeta Goswami, et al.. (2016). Growth and metastasis of lung adenocarcinoma is potentiated by BMP4-mediated immunosuppression. OncoImmunology. 5(11). e1234570–e1234570. 22 indexed citations

Gibbons, Don L., Lauren A. Byers, & Jonathan M. Kurie. (2014). Smoking, p53 Mutation, and Lung Cancer. Molecular Cancer Research. 12(1). 3–13. 206 indexed citations

Gibbons, Don L., Limo Chen, Sangeeta Goswami, et al.. (2014). Regulation of tumor cell PD-L1 expression by microRNA-200 and control of lung cancer metastasis.. Journal of Clinical Oncology. 32(15_suppl). 8063–8063. 7 indexed citations

Creighton, Chad J., Don L. Gibbons, & Jonathan M. Kurie. (2013). The role of epithelial–mesenchymal transition programming in invasion and metastasis: a clinical perspective. Cancer Management and Research. 5. 187–187. 112 indexed citations

Schumacher, Maria A., Jungki Min, Todd Link, et al.. (2012). Role of Unusual P Loop Ejection and Autophosphorylation in HipA-Mediated Persistence and Multidrug Tolerance. Cell Reports. 2(3). 518–525. 36 indexed citations

Borok, Zea, Jeffrey A. Whitsett, Peter B. Bitterman, et al.. (2011). Cell Plasticity in Lung Injury and Repair: Report from an NHLBI Workshop, April 19–20, 2010. Proceedings of the American Thoracic Society. 8(3). 215–222. 36 indexed citations

Roybal, Jonathon D., Yi Zang, Young‐Ho Ahn, et al.. (2010). miR-200 Inhibits Lung Adenocarcinoma Cell Invasion and Metastasis by Targeting Flt1/VEGFR1. Molecular Cancer Research. 9(1). 25–35. 148 indexed citations

10.

Lee, Daekee, Ming Yu, Eunjung Lee, et al.. (2009). Tumor-specific apoptosis caused by deletion of the ERBB3 pseudo-kinase in mouse intestinal epithelium. Journal of Clinical Investigation. 119(9). 2702–2713. 73 indexed citations

11.

Xia, Dianren, Nicole L. Moore, Iván P. Uray, et al.. (2006). Akt phosphorylates and suppresses the transactivation of retinoic acid receptor α. Biochemical Journal. 395(3). 653–662. 41 indexed citations

12.

Ramirez, Ruben D., Jonathan M. Kurie, J. Michael DiMaio, et al.. (2003). O-205 Immortalization of normal human bronchial epithelial cells (NHBEC) in the absence of viral oncoproteins. Lung Cancer. 41. S60–S61. 3 indexed citations

13.

Lee, Ho‐Young, Kyung‐Hee Chun, Bingrong Liu, et al.. (2002). Insulin-like growth factor binding protein-3 inhibits the growth of non-small cell lung cancer.. PubMed. 62(12). 3530–7. 133 indexed citations

14.

Herbst, Roy S., Fadlo R. Khuri, Maria Jung, et al.. (2000). Phase II study of combination weekly gemcitabine and vinorelbine in patients with untreated or previously treated non-small cell lung cancer. Lung Cancer. 29(1). 12–12. 23 indexed citations

15.

Khuri, Fadlo R., Jonathan M. Kurie, & W K Hong. (1997). CHEMOPREVENTION OF RESPIRATORY TRACT CANCER. Hematology/Oncology Clinics of North America. 11(3). 387–408. 8 indexed citations

16.

Kurie, Jonathan M., Scott M. Lippman, & Waun Ki Hong. (1994). Potential of retinoids in cancer prevention. Cancer Treatment Reviews. 20(1). 1–10. 13 indexed citations

17.

Rusch, Valerie W., Victor E. Reuter, Mark G. Kris, et al.. (1992). Ras oncogene point mutation: An infrequent event in bronchioloalveolar cancer. Journal of Thoracic and Cardiovascular Surgery. 104(5). 1465–1469. 10 indexed citations

18.

Troppmair, Jakob, Mahmoud Huleihel, John L. Cleveland, et al.. (1988). Plasmacytoma Induction by J Series of v-myc Recombinant Retroviruses: Evidence for the Requirement of Two (raf and myc) Oncogenes for Transformation. Current topics in microbiology and immunology. 141. 110–114. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact